{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:12:54Z","timestamp":1793236374094,"version":"4.5.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Radioactive iodine (RAI) therapy remains a widely accepted and effective intervention for differentiated thyroid cancer (DTC). Nonetheless, concerns persist regarding the potential emergence of second primary malignancies following RAI exposure. To assess the association between RAI administration and the risk of secondary hematologic malignancies in DTC patients, a meta-analysis was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic literature search was performed via PubMed and Web of Science, conforming to PRISMA guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seventeen studies, including a total of 586\u00a0260 DTC patients, were included in the final analysis. The aggregated risk ratio (RR) for secondary hematologic malignancies among those treated with RAI was 1.25 (95% CI: 1.13\u20131.38,\n                      <jats:italic toggle=\"yes\">P&lt;<\/jats:italic>\n                      0.0001), compared with non-RAI recipients. Heterogeneity across studies was minimal (\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a08%). Further subgroup analyses were conducted based on malignancy subtype and RAI dosage. The RR estimates by subtype were as follows: non-Hodgkin\u2019s lymphoma, 0.91 (95% CI: 0.72\u20131.16,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.45); Hodgkin\u2019s lymphoma, 1.17 (95% CI: 0.62\u20132.21,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.63); myeloma, 0.90 (95% CI: 0.59\u20131.37,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.62); and leukemia, 1.52 (95% CI: 1.05\u20132.21,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.03). For patients receiving RAI doses below 3.7 GBq, the pooled RR was 0.39 (95% CI: 0.22\u20130.72,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.002). Sensitivity and subgroup analyses reinforced the robustness and internal consistency of these findings. No publication bias was detected via Egger\u2019s regression or Begg\u2019s funnel plot (\n                      <jats:italic toggle=\"yes\">P =<\/jats:italic>\n                      \u00a00.511).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These results suggest a potential elevation in the risk of secondary hematologic malignancies \u2013 particularly leukemia \u2013 following RAI therapy in DTC patients. However, administration of RAI at doses below 3.7 GBq may not confer such risk. Additional large-scale, multicenter prospective investigations are warranted to validate these observations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000002813","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T09:01:27Z","timestamp":1750755687000},"page":"7312-7321","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Meta-analysis of secondary hematologic malignancy risks following radioactive iodine therapy for differentiated thyroid cancer"],"prefix":"10.1097","volume":"111","author":[{"given":"Hongyue","family":"Su","sequence":"first","affiliation":[{"name":"Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The People\u2019s Hospital of Liaoning Province, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Cancer Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1952-128X","authenticated-orcid":false,"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"R1-20260109","first-page":"2313\u201322","article-title":"Clinical and molecular features of progressive papillary thyroid microcarcinoma","volume":"110","author":"Wang","year":"2024","journal-title":"Int J Surg"},{"key":"R2-20260109","first-page":"47\u201353","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"1\u2013133","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"1683\u201390","DOI":"10.1007\/s00259-011-1841-x","article-title":"Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl","volume":"38","author":"Hebestreit","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20260109","first-page":"711\u201320","article-title":"The Ukrainian-American study of leukemia and related disorders among Chernobyl cleanup workers from Ukraine: III. Radiation risks","volume":"170","author":"Romanenko","year":"2008","journal-title":"Radiat Res"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"1831\u201339","DOI":"10.1200\/JCO.2017.75.0232","article-title":"Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer","volume":"36","author":"Molenaar","year":"2018","journal-title":"J Clin Oncol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"927\u201334","DOI":"10.1089\/thy.2014.0557","article-title":"Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: a nationwide, population-based study in Korea","volume":"25","author":"Seo","year":"2015","journal-title":"Thyroid"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"723\u201325","DOI":"10.2967\/jnumed.118.211359","article-title":"Radioactive iodine therapy for differentiated thyroid cancer: lessons from confronting controversial literature on risks for secondary malignancy","volume":"59","author":"Tulchinsky","year":"2018","journal-title":"J Nucl Med"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"2838\u201346","DOI":"10.1002\/ijc.33116","article-title":"Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?","volume":"147","author":"Cappagli","year":"2020","journal-title":"Int J Cancer"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"681\u201387","DOI":"10.1089\/thy.2015.0067","article-title":"Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer","volume":"25","author":"Marti","year":"2015","journal-title":"Thyroid"},{"key":"R11-20260109","first-page":"100082","article-title":"Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Premier J Sci"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"e0241445","DOI":"10.1371\/journal.pone.0241445","article-title":"Vitiligo and anxiety: a systematic review and meta-analysis","volume":"15","author":"Kussainova","year":"2020","journal-title":"PLoS One"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"455\u201364","DOI":"10.1530\/EJE-12-0379","article-title":"Thyroid antibodies and risk of preterm delivery: a meta-analysis of prospective cohort studies","volume":"167","author":"He","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"d2616","DOI":"10.1136\/bmj.d2616","article-title":"Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence","volume":"342","author":"Thangaratinam","year":"2011","journal-title":"BMJ"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"1539\u201358","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"e007558","DOI":"10.1161\/JAHA.117.007558","article-title":"New-onset atrial fibrillation after coronary artery bypass graft and long-term risk of stroke: a meta-analysis","volume":"6","author":"Megens","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"97\u2013111","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.316.7129.469","article-title":"Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity","volume":"316","author":"Stuck","year":"1998","journal-title":"BMJ"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"629\u201334","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"734\u201339","DOI":"10.1038\/bjc.1997.130","article-title":"Leukaemias and cancers following iodine-131 administration for thyroid cancer","volume":"75","author":"de Vathaire","year":"1997","journal-title":"Br J Cancer"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"1638\u201344","DOI":"10.1038\/sj.bjc.6601319","article-title":"Second primary malignancies in thyroid cancer patients","volume":"89","author":"Rubino","year":"2003","journal-title":"Br J Cancer"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"607\u201310","DOI":"10.1177\/000348940611500806","article-title":"Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma","volume":"115","author":"Bhattacharyya","year":"2006","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"504\u201315","DOI":"10.1210\/jc.2007-1154","article-title":"The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer","volume":"93","author":"Brown","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"844\u201350","DOI":"10.1016\/j.surg.2011.12.019","article-title":"Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy","volume":"151","author":"Lang","year":"2012","journal-title":"Surgery"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"442\u201348","DOI":"10.15537\/smj.2015.4.10341","article-title":"Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers","volume":"36","author":"Al-Qahtani","year":"2015","journal-title":"Saudi Med J"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"1172\u201378","DOI":"10.1007\/s00259-015-3055-0","article-title":"(131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study","volume":"42","author":"Ko","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"231\u201339","DOI":"10.1007\/s10147-015-0904-6","article-title":"Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer","volume":"21","author":"Hakala","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"1110\u201316","DOI":"10.1089\/thy.2016.0037","article-title":"Incidence of nonthyroidal primary malignancy and the association with (131)I treatment in patients with differentiated thyroid cancer","volume":"26","author":"Hirsch","year":"2016","journal-title":"Thyroid"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"1068\u201376","DOI":"10.1089\/thy.2016.0655","article-title":"Second primary cancer in patients with differentiated thyroid cancer: does radioiodine play a role?","volume":"27","author":"Silva-Vieira","year":"2017","journal-title":"Thyroid"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"8765369","DOI":"10.1155\/2018\/8765369","article-title":"Incidence of second malignancy in patients with papillary thyroid cancer from surveillance, epidemiology, and end results 13 dataset","volume":"2018","author":"Endo","year":"2018","journal-title":"J Thyroid Res"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/s12885-021-08292-8","article-title":"Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients","volume":"21","author":"Mei","year":"2021","journal-title":"BMC Cancer"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"e2580","DOI":"10.1210\/clinem\/dgab192","article-title":"Radioactive iodine treatment for children and young adults with thyroid cancer in South Korea: a population-based study","volume":"106","author":"Seo","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"1439\u201349","DOI":"10.1200\/JCO.21.01841","article-title":"Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies","volume":"40","author":"Pasqual","year":"2022","journal-title":"J Clin Oncol"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"2638\u201348","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1","article-title":"A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995","volume":"83","author":"Hundahl","year":"1998","journal-title":"Cancer"},{"key":"R37-20260109","first-page":"1381\u201391","article-title":"The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer","volume":"19","author":"Van Nostrand","year":"2009","journal-title":"Thyroid"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"695\u2013702","DOI":"10.1093\/jnci\/djad040","article-title":"Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer","volume":"115","author":"Kim","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"R39-20260109","doi-asserted-by":"crossref","first-page":"561\u201371","DOI":"10.1530\/EJE-21-1208","article-title":"Risk factors for second primary malignancies following thyroid cancer: a nationwide cohort study","volume":"186","author":"Kim","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"R40-20260109","doi-asserted-by":"crossref","first-page":"4439\u201346","DOI":"10.1002\/cncr.26070","article-title":"Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy","volume":"117","author":"Iyer","year":"2011","journal-title":"Cancer"},{"key":"R41-20260109","doi-asserted-by":"crossref","first-page":"275\u201386","DOI":"10.1007\/s13139-023-00818-1","article-title":"Second primary malignancy after radioiodine therapy in thyroid cancer patient: a nationwide study","volume":"57","author":"Hong","year":"2023","journal-title":"Nucl Med Mol Imaging"},{"key":"R42-20260109","doi-asserted-by":"crossref","first-page":"3\u20139","DOI":"10.1038\/leu.2012.151","article-title":"A record-based case-control study of natural background radiation and the incidence of childhood leukaemia and other cancers in Great Britain during 1980-2006","volume":"27","author":"Kendall","year":"2013","journal-title":"Leukemia"},{"key":"R43-20260109","doi-asserted-by":"crossref","first-page":"1008\u201312","DOI":"10.1016\/0140-6736(90)91071-H","article-title":"Radon as a causative factor in induction of myeloid leukaemia and other cancers","volume":"335","author":"Henshaw","year":"1990","journal-title":"Lancet"},{"key":"R44-20260109","doi-asserted-by":"crossref","first-page":"513\u201328","DOI":"10.1016\/S0301-472X(02)00802-0","article-title":"Hematologic consequences of exposure to ionizing radiation","volume":"30","author":"Dainiak","year":"2002","journal-title":"Exp Hematol"},{"key":"R45-20260109","first-page":"105\u201310","article-title":"Management outcomes of pediatric and adolescent papillary thyroid cancers with a brief review of literature","volume":"55","author":"Palaniappan","year":"2018","journal-title":"Indian J Cancer"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:01:46Z","timestamp":1767963706000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002813","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"2025-01-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}